Capricor Therapeutics is a biotechnology business based in the US. Capricor Therapeutics stocks (CAPR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.07 – a decrease of 5.33% over the previous week. Capricor Therapeutics employs 26 staff and has a trailing 12-month revenue of around $302,728.
How to buy shares in Capricor Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CAPR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Capricor Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Capricor Therapeutics?
- Has coronavirus impacted Capricor Therapeutics shares?
- Capricor Therapeutics shares summary
- Compare share dealing platforms
- Is Capricor Therapeutics stock a buy or sell?
- Capricor Therapeutics performance over time
- Capricor Therapeutics's financials
- How volatile are Capricor Therapeutics shares?
- Does Capricor Therapeutics pay a dividend?
- Have Capricor Therapeutics shares ever split?
- Other common questions
How has Coronavirus impacted Capricor Therapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Capricor Therapeutics's stock price has had significant positive movement.
Its last market close was $3.02, which is 53.97% up on its pre-crash value of $1.39 and 243.18% up on the lowest point reached during the March crash when the stocks fell as low as $0.88.
If you had bought $1,000 worth of Capricor Therapeutics stocks at the start of February 2020, those stocks would have been worth $773.34 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,013.34.
Capricor Therapeutics stock price (NASDAQ:CAPR)Use our graph to track the performance of CAPR stocks over time.
Capricor Therapeutics shares at a glance
|Latest market close||$3.02|
|52-week range||$2.75 - $8.40|
|50-day moving average||$3.24|
|200-day moving average||$4.04|
|Wall St. target price||$13.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.82|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Capricor Therapeutics price performance over time
|1 week (2022-01-12)||-5.33%|
|1 month (2021-12-17)||-8.21%|
|3 months (2021-10-19)||-23.74%|
|6 months (2021-07-19)||-33.77%|
|1 year (2021-01-19)||-44.49%|
|2 years (2020-01-17)||65.03%|
|3 years (2019-01-18)||354.14%|
|5 years (2017-01-19)||23.64%|
Capricor Therapeutics financials
|Gross profit TTM||$-8,146,750|
|Return on assets TTM||-29.54%|
|Return on equity TTM||-53.65%|
|Market capitalisation||$74.6 million|
TTM: trailing 12 months
Capricor Therapeutics share dividends
We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.
Have Capricor Therapeutics's shares ever split?
Capricor Therapeutics's shares were split on a 1:10 basis on 5 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.
Capricor Therapeutics share price volatility
Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as $2.75 up to $8.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 6.1637. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Capricor Therapeutics overview
Capricor Therapeutics, Inc. , a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Stocks similar to Capricor Therapeutics
Frequently asked questions
Capricor Therapeutics in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
More guides on Finder
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
COVID testing stocks
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
Pendle (PENDLE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
Hempcoin (THC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.
The ChampCoin (TCC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy The ChampCoin, lists some exchanges where you can get it and provides daily price data on TCC.
GreenTrust (GNT) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy GreenTrust, lists some exchanges where you can get it and provides daily price data on GNT.